Free Trial

Edwards Lifesciences (EW) Stock Forecast & Price Target

$87.32
-0.42 (-0.48%)
(As of 07/17/2024 ET)

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 20 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 1 has given a sell rating, 5 have given a hold rating, and 14 have given a buy rating for EW.

Consensus Price Target

$96.76
10.82% Upside
High Forecast$110.00
Average Forecast$96.76
Low Forecast$57.00

According to the 20 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $96.76. The highest price target for EW is $110.00, while the lowest price target for EW is $57.00. The average price target represents a forecasted upside of 10.82% from the current price of $87.32.

TypeCurrent Forecast
7/19/23 to 7/18/24
1 Month Ago
6/19/23 to 6/18/24
3 Months Ago
4/20/23 to 4/19/24
1 Year Ago
7/19/22 to 7/19/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
14 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
6 Hold rating(s)
9 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$96.76$95.06$91.73$93.05
Forecasted Upside10.82% Upside10.51% Upside8.35% Upside13.52% Upside
Get Edwards Lifesciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Edwards Lifesciences Stock vs. The Competition

TypeEdwards LifesciencesMedical CompaniesS&P 500
Consensus Rating Score
2.65
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside10.82% Upside1,129.97% Upside7.87% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/16/2024Truist Financial
1 of 5 stars
 Boost TargetBuy ➝ Buy$105.00 ➝ $110.00+23.50%
7/10/2024Citigroup
3 of 5 stars
 Boost TargetBuy ➝ Buy$105.00 ➝ $106.00+13.03%
7/2/2024Evercore ISI
2 of 5 stars
 Boost TargetIn-Line ➝ In-Line$89.00 ➝ $91.00+0.76%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$107.00+22.90%
5/14/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$86.00 ➝ $103.00+19.08%
5/7/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$100.00 ➝ $101.00+17.84%
4/26/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$94.00 ➝ $99.00+14.45%
4/26/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$83.00 ➝ $85.00-1.99%
4/26/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$85.00 ➝ $88.00+2.06%
4/15/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$95.00 ➝ $101.00+12.90%
4/11/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$95.00 ➝ $105.00+14.78%
3/26/2024OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMixed ➝ Positive
3/21/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$95.00 ➝ $103.00+8.72%
3/18/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$93.00 ➝ $100.00+7.64%
3/7/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
11/28/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradePeer Perform ➝ Underperform$57.00-15.13%
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
10/16/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$75.00+4.90%
7/25/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$103.00 ➝ $107.00+17.07%
7/18/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$107.00+16.32%
6/27/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates
3/28/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$84.00+4.36%
2/6/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
2/1/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold$68.00 ➝ $76.00-4.50%
1/31/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Underperform$95.00 ➝ $66.00-13.23%
10/28/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$125.00 ➝ $100.00+38.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:13 AM ET.

EW Forecast - Frequently Asked Questions

What is Edwards Lifesciences' forecast for 2024?

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $96.76, with a high forecast of $110.00 and a low forecast of $57.00.

Should I buy or sell Edwards Lifesciences stock right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There is currently 1 sell rating, 5 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EW shares.

Does Edwards Lifesciences's stock price have much upside?

According to analysts, Edwards Lifesciences's stock has a predicted upside of 10.96% based on their 12-month stock forecasts.

Has Edwards Lifesciences been upgraded by Wall Street analysts recently?

Over the previous 90 days, Edwards Lifesciences's stock had 2 upgrades by analysts.

What analysts cover Edwards Lifesciences?

Edwards Lifesciences has been rated by research analysts at Barclays, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore ISI, Piper Sandler, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Edwards Lifesciences more than its competitors?

Analysts like Edwards Lifesciences less than other "medical" companies. The consensus rating score for Edwards Lifesciences is 2.65 while the average consensus rating score for "medical" companies is 2.72. Learn more on how EW compares to other companies.


This page (NYSE:EW) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners